Explore 3 Stock Ideas & Industry Insights Download Free Report

888-969-2592
Shopping Cart 0
countryflagCA
Login

Home CompaniesIntensity Therapeutics, Inc. Common stock

Intensity Therapeutics, Inc. Common stock

Healthcare Biotechnology
PortfolioPortfolio WatchlistWatchlist
Company price
3.2471 USD 0.25 ( 8.24%)
Last update at 2026-11-09T17:43:00Z
VOLUME
51324
Market Cap
12.44M

Momentum Score

…

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
2.80
Low
3.25
High
52 Week Price Range
3.51
Low
43.50
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Intensity Therapeutics, Inc. is a Nasdaq-listed biotechnology company focused on developing therapies in oncology. Major long-term growth drivers may include positive clinical trial outcomes, regulatory milestones and strategic partnerships supporting commercialization. Investors may find the company attractive for potential upside from clinical progress and technology validation, although outcomes are uncertain.
Principal risks are clinical and regulatory setbacks, limited operating history with recurrent financing needs causing dilution, and strong competition with execution risk.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
3.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
0.01
ROE
-195.88%
Net Debt
-11.81M
ROCE
-100.14%
Diluted EPS TTM
-1.91

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Income before tax -11.61M -16.27M -10.54M -7.58M -7.90M
Net income -11.61M -16.27M -10.54M -7.45M -7.89M
Selling general administrative 5.19M 6.09M 3.53M 2.42M 2.16M
Selling and marketing expenses - - 0.15M - -
Gross profit -0.03M -0.03M -0.15M - -
Ebit - -16.27M -10.23M -7.63M -8.01M
Ebitda -11.61M -16.27M -10.09M -7.50M -8.01M
Depreciation and amortization - 0.03M 0.15M 0.13M -
Operating income -11.97M -16.59M -8.32M -7.63M -8.01M
Other operating expenses 11.97M 16.59M 8.32M 7.55M 8.01M
Interest expense - 0.00M 0.30M 0.08M -
Interest income 0.18M 0.31M 0.32M 0.00M 0.00M
Net interest income 0.18M 0.31M 0.02M -0.08M 0.00M
Income tax expense - - 0.00M -0.13M -0.00M
Total revenue 0.00M 0.00M 0.00M 0.00M 0.00M
Total operating expenses 11.97M 16.59M 8.17M 7.55M 8.01M
Cost of revenue 0.03M 0.03M 0.15M - -
Total other income expense net 0.37M 0.32M -2.22M 0.05M 0.12M
Net income from continuing ops -11.61M -16.27M -10.54M -7.58M -7.90M
Net income applicable to common shares - - - - -7.90M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total assets 14.10M 4.78M 17.30M 1.76M 5.22M
Other current assets 0.79M 0.77M 0.69M 0.05M 0.07M
Total liab 2.23M 1.86M 4.13M 16.85M 13.90M
Total stockholder equity 11.88M 2.92M 13.16M -15.10M -8.68M
Other current liab 1.53M 0.51M 0.89M 1.72M 1.35M
Common stock - 0.00M 0.00M 0.00M 0.00M
Capital stock 0.00M 0.00M 0.00M 0.00M 0.00M
Retained earnings -78.39M -66.78M -50.52M -38.65M -31.07M
Other liab - - - - 0.04M
Other assets - - - - 0.17M
Cash 11.92M 2.59M 8.56M 1.31M 4.54M
Total current liabilities 2.15M 1.75M 3.96M 6.82M 3.72M
Net debt -11.81M -2.45M -8.40M 3.18M -2.20M
Short term debt 0.03M 0.03M 0.02M 4.49M 2.20M
Short long term debt - - - 4.35M 2.02M
Short long term debt total 0.11M 0.14M 0.16M 4.49M 2.34M
Other stockholder equity 90.27M 69.70M 63.68M 23.56M 22.39M
Property plant equipment - - - - 0.32M
Total current assets 12.71M 3.36M 15.46M 1.45M 4.73M
Net tangible assets - - - - -8.68M
Short term investments - 0.00M 6.22M - -
Net receivables - - - 0.06M 0.05M
Inventory - - - 0.03M 0.07M
Accounts payable 0.58M 1.22M 3.05M 0.60M 0.17M
Accumulated other comprehensive income - - -17.30M - -
Non currrent assets other 1.30M 1.30M 1.68M 0.17M 0.17M
Non current assets total 1.39M 1.42M 1.83M 0.31M 0.49M
Capital lease obligations 0.11M 0.14M 0.16M 0.14M 0.33M
Breakdown 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Type yearly yearly yearly yearly yearly
Date 2025-12-31 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Investments 0.00M 6.35M -6.02M - 0.00M
Change to liabilities - - - - -0.05M
Total cashflows from investing activities - 6.35M -6.02M - -
Net borrowings - 0.00M 0.23M - 2.00M
Total cash from financing activities 18.56M 2.90M 20.47M 2.25M 2.05M
Change to operating activities - - - - 0.23M
Net income -11.61M -16.27M -10.54M -7.58M -7.90M
Change in cash 9.33M -5.97M 7.24M -3.23M -4.78M
Begin period cash flow 2.59M 8.56M 1.31M 4.54M 9.32M
End period cash flow 11.92M 2.59M 8.56M 1.31M 4.54M
Total cash from operating activities -9.23M -15.22M -7.21M -5.48M -6.83M
Issuance of capital stock 20.32M 3.23M 22.43M - 0.00M
Depreciation - - 0.15M - -
Other cashflows from investing activities - 9.41M - - -
Dividends paid - - 1.32M - -
Sale purchase of stock - - 3.56M - -
Other cashflows from financing activities 18.56M -0.33M -2.18M - 2.05M
Change to netincome - - - - 0.89M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.35M -2.10M -0.63M 0.76M 0.18M
Stock based compensation 2.00M 3.07M 1.40M 1.17M 0.72M
Other non cash items 0.03M 0.08M 2.57M 0.18M 0.17M
Free cash flow -9.23M -15.22M -7.21M -5.48M -6.83M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to EBITDA (x)
INTS
Intensity Therapeutics, Inc. Common stock		 0.25
8.24%		 3.25 - - - 1.41 -4.72
NVO
Novo Nordisk A/S		 1.03
2.56%		 41.34 41.58 31.15 2.13 32.99 4.70
VRTX
Vertex Pharmaceuticals Inc		 1.49
0.27%		 548.58 30.22 24.27 10.36 6.50 24.66
REGN
Regeneron Pharmaceuticals Inc		 18.16
2.01%		 922.51 29.07 20.12 7.57 3.82 19.42
ARGNF
argenx SE		 -
-%		 900.30 45.77 31.25 13.84 7.12 36.06

Profile*

Intensity Therapeutics, Inc. Common stock

Intensity Therapeutics, Inc., a late-stage clinical biotechnology company, engages in the provision of treatment for the regional and systemic nature of cancer relapse and metastasis in the United States. Its lead product candidate includes INT230-6, which is in Phase 3 clinical studies for the treatment of soft tissue sarcoma; and neoadjuvant and metastatic triple negative breast cancer which is in Phase 2 clinical trials. The company was incorporated in 2012 and is headquartered in Shelton, Connecticut.

1 Enterprise Drive, Shelton, CT, United States, 06484-4779

203 221 7381

https://intensitytherapeutics.com

5

Name Title Year Born
Mr. Lewis H. Bender M.A., M.B.A., M.S. Founder, President, CEO & Chairman of the Board 1959
Mr. John Wesolowski CPA, M.B.A. Principal Accounting Officer & Controller 1960
Mr. James M. Ahlers Executive Vice President of Corporate Finance 1964
Mr. Joseph Talamo CPA, M.B.A. Chief Financial Officer 1969
Mr. Brian Schwartz M.D. Executive Vice President of Clinical Development NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Kalkine

3 Mining Stock
Ideas Report

Download a free report with stock ideas and industry insights for general information.

Download Free Report Now → sector image

Top Stocks by Market Cap*

GFR
CAD 10.93
+37.83%
MOON
CAD 4.86
+10.20%
HG
CAD 4.43
+9.93%
EPRX
CAD 10.57
+8.86%
NUAG
CAD 8.66
+8.79%
CSU
CAD 3257.60
-7.63%
DIV
CAD 3.85
-5.53%
TOI
CAD 99.00
-5.52%
BSX
CAD 0.82
-4.65%
LMN
CAD 26.79
-4.63%

Equity Sectors*

  • Basic Materials

    +3.88%

  • Communication Services

    -1.14%

  • Consumer Cyclical

    +0.75%

  • Consumer Defensive

    -0.36%

  • Energy

    +2.16%

  • Financial Services

    +1.33%

  • Healthcare

    +1.50%

  • Industrials

    +2.97%

  • Real Estate

    +0.41%

  • Technology

    +1.27%

  • Utilities

    +1.09%

Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.

Support

Hi! How can we help you today?

Loading…